Abstract: The Kirsten rat sarcoma viral oncogene homolog (KRAS) is a highly prevalent oncogenic driver that has historically been challenging to target. Recent advancements have led to the development of BI-2865, a novel, non-covalent pan-KRAS inhibitor designed to target the inactive state of the KRAS protein. BI-2865 demonstrates remarkable selectivity for KRAS over other RAS isoforms (HRAS and NRAS) and exhibits potent inhibitory activity against a broad spectrum of common KRAS mutations, including G12, G13, and Q61H variants. By binding to the switch-II pocket, BI-2865 effectively reduces tumor proliferation in both in vitro and in vivo models. However, the emergence of acquired resistance through secondary mutations within the switch-II pocket (such as R68, H95, Y96, and Q99) presents a significant clinical challenge. Furthermore, the concurrent inhibition of wild-type KRAS raises potential toxicity concerns. To address these limitations, future therapeutic strategies are heavily focused on combination therapies, particularly integrating immunotherapies and other pathway inhibitors, to circumvent resistance mechanisms and improve patient outcomes.
1. Introduction
Mutations in the RAS family of small GTPases account for approximately 30% of all cancer diagnoses, with the Kirsten rat sarcoma viral oncogene homolog (KRAS) being the most frequently mutated isoform [1]. For decades, KRAS was considered "undruggable" due to its high affinity for GTP/GDP and the lack of deep pharmacological binding pockets. However, the discovery of the allosteric switch-II pocket paved the way for the first generation of covalent inhibitors targeting the specific KRAS G12C mutation [1]. While these mutant-specific inhibitors have shown clinical success, they leave a significant unmet need for patients harboring other prevalent KRAS mutations. To address this, broad-spectrum pan-KRAS inhibitors have been developed. Among these next-generation therapeutics is BI-2865, a non-covalent pan-KRAS inhibitor that has demonstrated the ability to reduce tumor proliferation in cell lines and mouse models by targeting multiple KRAS variants simultaneously [1].
2. Pharmacological Activity
BI-2865 exhibits potent and broad-spectrum pharmacological activity against a variety of KRAS mutations. It is approximately two to three orders of magnitude more selective for KRAS than for its closely related isoforms, HRAS and NRAS [1]. In vitro binding assays reveal high binding affinities (Kd values) across multiple KRAS variants: wild-type KRAS (6.9 nM), KRAS G12C (4.5 nM), KRAS G12D (32 nM), KRAS G12V (26 nM), and KRAS G13D (4.3 nM) [1]. The compound successfully inhibits many common G12, G13, and Q61H mutations. However, it is notable that BI-2865 does not effectively inhibit the G12R mutation or other Q61 mutations [1]. Because of its pan-KRAS nature, BI-2865 also inactivates wild-type (WT) KRAS alongside the oncogenic mutants [1].
3. Molecular Mechanism of Action
Unlike the first-generation G12C-specific drugs that rely on covalent bonding to a mutant cysteine residue, BI-2865 functions as a non-covalent inhibitor [1]. It is specifically designed to target the inactive, GDP-bound form of the KRAS protein [1]. BI-2865 exerts its inhibitory effect by binding to the allosteric switch-II pocket of KRAS, a mechanism of action that shares a very similar KRAS binding mode with other notable inhibitors such as Adagrasib and MRTX-1133 [1]. By occupying this pocket, the inhibitor stabilizes the inactive conformation of the protein, thereby preventing the nucleotide exchange necessary for KRAS activation and subsequently halting downstream oncogenic signaling.
4. Structure-Activity Relationship (SAR)
The structural design of BI-2865 was heavily informed by G12C pharmacophores targeting the inactive form of KRAS, supported by atomic-resolution crystal structures [1]. A critical aspect of BI-2865's structure-activity relationship is its remarkable selectivity for the KRAS isoform over HRAS and NRAS. Structural complex and mutagenesis studies have demonstrated that BI-2865 confers this selectivity primarily around the H95 residue [1]. Histidine 95 is one of the few amino acids within the RAS G-domain that differs among the various RAS isoforms, making it a crucial anchor point for KRAS-specific targeting. Furthermore, structural alignments reveal that residues R68, H95, Y96, and Q99 within the switch-II pocket make crucial contacts with BI-2865, stabilizing the drug-protein interaction [1].
5. Current Limitations
Despite its broad efficacy, the clinical utility of BI-2865 faces significant challenges, primarily concerning acquired resistance and potential toxicity. As a pan-KRAS inhibitor, BI-2865 inactivates WT KRAS. Currently, there is a lack of clinical data demonstrating the physiological consequences and potential toxicities of blocking WT KRAS in cancer patients, although it is hypothesized that WT KRAS activity might be partially compensated by NRAS and HRAS isoforms [1].
More pressingly, acquired resistance via secondary point mutations makes KRAS a continuously moving target. Because BI-2865 relies on specific contacts within the switch-II pocket, secondary mutations at residues R68, H95, Y96, and Q99—which have already been observed to cause resistance to G12C inhibitors like Adagrasib and Sotorasib—could readily arise during BI-2865 treatment [1]. These mutations can sever critical hydrogen bonds or hydrophobic interactions, destabilizing the inhibitor's binding. Additionally, resistance can develop through mutations in other members of the RAS signaling pathway, such as upstream receptor tyrosine kinases (RTKs) or downstream effectors like BRAF and CRAF [1].
6. Future Perspectives
To overcome the inevitable emergence of acquired resistance and secondary mutations associated with monotherapies like BI-2865, future research is heavily directing towards combination therapies. Combining KRAS inhibitors with other therapeutic modalities offers a strategic advantage to circumvent resistance mechanisms [1]. One highly promising avenue is the combination of targeted inhibitor treatments with immunotherapy. Because KRAS mutations often create an immunosuppressive tumor microenvironment, inhibiting KRAS can restore immune detection. Novel approaches include using bispecific T-cell engagers (BiTEs) to target drug-modified neoantigens on the cell surface, or combining KRAS inhibitors with immune checkpoint inhibitors targeting the PD-1 signaling pathway [1]. Although early-phase trials combining KRAS inhibitors with anti-PD-1 have shown some toxicity challenges, ongoing preclinical research continues to explore synergistic combinations, including targeting alternative pathways like the unfolded protein response (IRE1a), to ensure durable clinical responses against KRAS-driven tumors [1].
